(RxWiki News) The US Food and Drug Administration (FDA) has approved an injection to treat episodic cluster headaches in adults.
This new drug is called Emgality (galcanezumab-gnlm). It’s available as an injection to be administered under the fatty layer of the skin. It is to be injected into the stomach area, thigh, back of the upper arm or buttocks.
Last year, this medication was approved to prevent migraines in adults, but the FDA has now approved it to treat episodic cluster headaches.
A cluster headache is a form of headache that is marked by extreme pain. This type of headache tends to happen in clusters (often at the same times of the day) and can occur for several weeks to months.
The approval of Emgality was based on a clinical trial that compared it to a placebo in 106 patients. A common side effect of this medication is an injection-site reaction like pain, redness or itching.
This medication is not to be used in those with serious hypersensitivity to this medication or to any of its ingredients.
Emgality includes a warning about the chance for hypersensitivity reactions. These reactions can happen days after administration and may be prolonged.
The FDA granted this medication approval to Eli Lilly.
Ask your health care provider any questions you have about treating episodic cluster headaches.